Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Autor: Peter H. Howarth, Lars H. Nordenmark, Michel Laviolette, Himanshu Parikh, Vibeke Backer, Tina Skjold, Salman Siddiqui, Ingrid Louise Titlestad, Ronald Olivenstein, Dave Singh, Læge Carl Nielsen, Richard J. Russell, Gene L. Colice, Martin Braddock, Millie Wang, Latifa Chachi, Christopher E. Brightling, Lorcan McGarvey, Rekha Chaudhuri, Charlotte Suppli Ulrik, David Cohen, Brian Leaker, J. Mark FitzGerald, Tim Harrison

Publikováno v: Russell, R J, Chachi, L, FitzGerald, J M, Backer, V, Olivenstein, R, Titlestad, I L, Ulrik, C S, Harrison, T, Singh, D, Chaudhuri, R, Leaker, B, McGarvey, L, Siddiqui, S, Wang, M, Braddock, M, Nordenmark, L H, Cohen, D, Parikh, H, Colice, G, Brightling, C E, Laviolette, M, Skjold, T, Nielsen, L C & Howarth, P 2018, ' Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS) : a multicentre, double-blind, randomised, placebo-controlled phase 2 trial ', The Lancet Respiratory Medicine, vol. 6, no. 7, pp. 499-510 . https://doi.org/10.1016/S2213-2600(18)30201-7

Summary Background The role of interleukin 13 in airway inflammation and remodelling in asthma is unclear. Tralokinumab is a human monoclonal antibody that neutralises interleukin 13. We aimed to evaluate whether tralokinumab would have an effect on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a60efc644236cce1b08a5d96e75de01
https://pubmed.ncbi.nlm.nih.gov/29793858